Justices from the right and left ask whether Congress needs to keep its promises.
The annual accounting of national health spending is out. And the 2018 health bill for the U.S. was $3.6 trillion, consuming nearly a fifth of the nation’s economy. Meanwhile, Congress is nearing the end of the year without having finished either its annual spending bills or several other high-priority health items. Kimberly Leonard of the Washington Examiner, Joanne Kenen of Politico and Mary Agnes Carey of Kaiser Health News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk about the latest KHN-NPR “Bill of the Month.”
The pharmaceutical industry’s argument that capping drug prices would compromise drug innovation stands “on very shaky ground.”
Special interests and congressional inaction blocked efforts to track the safety of electronic medical records, leaving patients at risk.
When passing the Affordable Care Act, Democrats touted the fact that they had included many measures to pay for the bill’s expanded coverage. But nearly 10 years later, many of the “pay-fors” have been eliminated.
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
A letter from the Senate Finance Committee chairman questions the University of Virginia Health System about its financial assistance policies, billing practices and prices.
A hearing before a House Oversight and Reform Committee panel on how to address the crisis of respiratory injuries related to vaping turned surprisingly partisan.
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.
Barbara Van Rooyan lost her son to the drug 15 years ago and has fought ceaselessly since then to hold Purdue Pharma accountable for its role in the opioid crisis.